Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases
Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases have?
Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases has 1 citations in the OpenAlex counts ScholarIQ stores.
When was Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases published?
Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases has 2022 year in the ScholarIQ index.
What is the open-access status of Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases?
Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases has gold oa status in the ScholarIQ index.
What is the DOI of Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases?
The DOI for Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases is on the source record.
What is the PMID of Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases?
The PMID for Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases is on the source record.
What is the OpenAlex record for Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases?
The OpenAlex for Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases is on the source record.